fda stop compounding semaglutide Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP-1 while @martymakary is photographed holding bootleg # Compound versions of GLP-1 drugs

In rodents, and possibly in humans, exendin-4 can stimulate -cell proliferation

Histological analysis shows FOXO4-DRI eliminates FOXO4-positive senescent cells and reduces IL-6 expression in liver tissue, indicating resolution of chemotherapy-induced inflammatory damage

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

Available at: This article is provided for informational and educational purposes only